Replies to post #90065 on DD Support Board and Research Team

[Jamesripp]

Let me start by saying that I may not be able to engage promptly on this site because it has a daily message limit, and that I am not looking for legal trouble.

If you read my Seeking Alpha article, you would see that I am quite familiar with this company's history. http://seekingalpha.com/article/3248845-hemispherx-biopharma-catalysts-for-a-turnaround

In the latest installment of the HEB saga, it just announced preliminary approval of a settlement agreement with former shareholders, and that the settlement is "not an admission of culpability" by the company. Would it not be possible that HEB has been absolved by the very shareholders it allegedly injured? http://www.hemispherx.net/content/investor/default.asp?goto=828

In re: Ampligen, while you say it is "a joke," the European Medicines Agecncy is taking it much more seriously http://www.ema.europa.eu/docs/en_GB/document_library/Orphan_designation/2015/05/WC500187066.pdf. I concede that I do not have a medical background, but I find it curious that the EMA would publish such an opinion unless their doctors and/or scientists thought that the drug had potential for the treatment of Ebola.

In re: your calculations on return on equity, investors should consider the long and costly process of FDA approval that comes with the territory in biotech investing.

Let me finish by saying again, I am not looking for legal trouble. I am merely looking out for the interests of myself and my fellow shareholders by trying to present the most current facts about this company and its products.